Furthermore, FGF19 has been implicated in the development of other cancers, including colorectal cancer (CRC), breast cancer (BC), prostate cancer (PCa), ovarian cancer (OC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), thyroid cancer (TC), cholangiocarcinoma (CCA), and lung squamous cell carcinoma (LUSC), where it contributes to tumor progression and development through various signaling pathways 15-22. This evidence concerns the gene FGF19 and cholangiocarcinoma.